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Abstract Intratumoral and intralesional administration of
anticancer drugs in gels and implantable formulations is
gaining much importance on account of its advantage of
site-specific delivery with highly dependable freedom from
unwanted side effects. Nanolipid carriers (NLC) are the
preferred vehicle due to their improved properties particu-
larly drug loading. In the present investigation, glyceryl
monostearate–oleic acid NLCs loaded with docetaxel were
prepared by emulsification and ultrasonication technique
and were incorporated in thermoreversible pluronic F127
gel (TRPgel) for intralesion injection to breast tissue. The
NLCs were spherical particles of 113 nm size with a nega-
tive zeta potential of −32.8 and 85 % drug entrapment. In
vitro drug release profile of the NLC showed 96 % drug
release in 48 h following Higuchi release kinetics. NLC
incorporated TRPgel showed mucoadhesive force of
3.07 dynes/cm2 and gelling temperature in the range of 32
to 37 °C. The drug entrapped gel was also subjected to in
vitro cytotoxicity study in human B-16 and HeLa cell lines
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay and in vivo drug distribution study
in breast tissue in healthyWistar rats. TheMTTassay revealed
that docetaxel-loaded NLC incorporated into gel showed low-
er cytotoxicity than docetaxel. However, in vivo breast tissue
distribution studies showed high tissue drug concentration,
sustained over a period of 60 h in comparison to docetaxel
and docetaxel-loaded NLCs. These results suggest that nano-
lipid carrier of docetaxel in TRPgel could be a promising
carrier system to deliver drug to tumor by intralesional admin-
istration for improving therapeutic benefits of docetaxel.
Keywords Docetaxel . Thermoreversible gels . Nanolipid
carriers . Breast cancer . Pluronic F127
1 Introduction
Breast cancer accounts for 33 % of all incident cancers in
women, with an increasing mortality rate in North America
(Jemal et al. 2005). Current clinical strategies dealing with
these solid tumors primarily consist of surgical excision,
irradiation, and chemotherapy. But the severity of increase
and occurrence of tumors leads to adjuvant therapy of che-
motherapeutic drugs (Rouzier et al. 2001). Most cytotoxic
agents when administered systemically into cancer patients
provide various limitations and challenges. These limita-
tions include large volume of distribution leading to system-
ic toxicity of vital organs, low blood flow into interior of a
tumor site resulting in inability to provide optimal dose, and
frequent dose reduction due to various toxicities like hema-
tologic, neurologic, and physiological. For these reasons,
drug delivery technology research has focused on targeting
anticancer drugs to a specific site or to develop intratumoral
or intralesional injections to provide timed release profile for
better management and cure of cancer (Rob et al. 2006).
Nanolipid carriers (NLCs) are considered a smarter gen-
eration of nanoparticles which possesses improved proper-
ties for drug loading, modulation of the delivery profile,
excellent biocompatibility, and easy modulation of bio-
degradation time in vivo (Muller et al. 2007). NLC are
promising carrier to increase the prolonged drug residence
in the target organ which can extend exposure of tumor cells
to antitumor drug. Mendes et al. (2009), based on his experi-
ments, reported that intralesional injection of anti cancer
agents is a promising approach for drug targeting in neo-
adjuvant chemotherapy in breast cancer treatment. The im-
portance of intramammary injection in the regression of
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human breast cancer xenografts growing bilaterally in nude
mice and potentiation of local antitumor actions of interferons
(IFNs) by recombinant human tumor necrosis factor α was
reported by Luciano et al. (1995). The structure of NLC is
irregular and has defects in the packing of molecules which
offers maximum space to accommodate drug molecules
resulting in high drug loading capability (Li et al. 2010).
Injectable in situ gels have caused much attention and have
been studied quite a lot in the fields of drug delivery, possibly
due to their ease of preparation, ease of control in quality, non-
use of organic solvents, site-specific delivery, prolonged
action periods, and improved patient compliance (Matsumura
andMaeda 1986). The in situ gel systemmay be pH-sensitive,
ion-sensitive, or thermosensitive, according to the different
materials used. Thermosensitive gel approach can be advan-
tageous for particular application as it is in sol form when
administered through various routes like subcutaneous, topi-
cal, intralesional, etc. and gets transformed to gel state at body
temperature. Thermosensitive gel made of pluronics 127
known as OncoGel is example of drug delivery technology
that uses both physical targeting to the target body site and
controlled release of drug. Pluronic F127 (PF127) can form a
gel with good thermosensitivity. It is usually regarded as
nontoxic and has been applied in localized drug delivery such
as intramuscular, intraperitoneal, and subcutaneous injections
(Wang and Johnston 1995; Liu et al. 2007).
The overall aim of the current study was to develop a
simple and generally applicable intratumoral injection strategy
for developing an effective way to treat breast cancers through
intralesional administration into these solid tumors. NLCs
loaded with docetaxel were prepared and were incorporated
in thermoreversible pluronic F127 gel (TRPgel). The NLCs
were characterized for morphology, particle size, surface
charge, entrapment efficiency, and for in vitro drug release
profile. NLC-incorporated TRPgel were studied for mucoad-
hesive property and gelling temperature. They were also eval-
uated for in vitro cytotoxicity study in B-16 and HeLa cell
lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay and in vivo drug distribution study in
breast tissue in healthy Wistar rats.
2 Materials and methods
2.1 Materials
Pluronic F127 (Mw=12,600, poly(ethylene oxide) (PEO)
99–poly(propylene oxide) (PPO)67–PEO99) were pur-
chased from Sigma. Docetaxel was obtained from Panacea
Biotech, Mohali, India. Glyceryl monostearate and oleic
acid were purchased from CDH. Pluronic F68 as surfactant
was purchased from Himedia. The HeLa and B-16 cell lines
were obtained from NCCS, Pune. MTT dye was obtained
from Himedia. Female rats were procured from animal
house of ISF College of Pharmacy, MOGA (Punjab), India.
2.2 Method
2.2.1 Preparation of nanolipid carrier
NLC of docetaxel was prepared by emulsification and ultra-
sonication technique (Liu et al. 2011). Lipid and aqueous phase
were prepared separately. Aqueous solution (25 ml) was pre-
pared by taking desired amount of surfactant, and it was
dissolved in water with continuous stirring under magnetic
stirring at low revolutions per minute. Lipid phase was pre-
pared by taking desired amount of lipid (glyceryl monostearate
and oleic acid) that was heated at 70 °C. Docetaxel being
insoluble in water was added to lipid phase and dissolved.
Both aqueous phase and lipid phase were heated separately
to a temperature of 60–70 °C, and then aqueous phase was
poured into lipid phase at the same temperature. This solution
was allowed to homogenize for 3 min at 500 rpm, and this
emulsion was immediately subjected to further size reduction
using a Probe sonicator. Emulsion was probe sonicated at 60%
amplitude for time 4 min. The period of ultrasound burst was
set to 9 s with a pause of 3 s between two ultrasound bursts.
Obtained solution was refrigerated at 2–3 °C for 15 min.
2.2.2 Preparation of nanolipid carrier in gel
Poloxamer in situ forming gels were prepared by the mod-
ified cold method (Yang et al. 2009). The required amount
of pluronic F127 was slowly added to the calculated amount
of NLC suspension with continuous mixing using a thermo-
statically controlled magnetic stirrer. The partially dissolved
pluronic solutions were stored in a refrigerator and stirred
periodically until clear homogenous solutions were obtained
(approximately 24 h).
2.3 Optimization
2.3.1 Nanolipid carrier
Different process parameters were systematically investigat-
ed to determine their effects on the particle size, polydisper-
sity index (PDI), and zeta potential of nanolipid carriers.
The process parameters included time of homogenization,
time of probe sonicator, drug concentration in the solution,
concentration of surfactant, and solid-to-lipid ratio.
2.3.2 NLC in gel
Various parameters were optimized to form NLC in gel-like
pluronic F127 concentration, gelation temperature, and
gelation time.
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2.4 Characterization of nanolipid carrier
2.4.1 Morphology
Transmission electron microscopy (TEM-FEI, Morgagni
268 D, the Netherland) was employed for particle imaging
for visualization of shape and morphology of the prepared
nanolipid carriers. A drop of the sample was placed onto a
carbon-coated copper grid to leave a thin film on the grid.
The film was negatively stained with 1 % phosphotungstic
acid solution and dried. A drop of the staining solutions was
added on to the film, and the excess of the solution was
drained off. The grid was allowed to dry at ambient temper-
ature, and samples were viewed under TEM and photo-
graphs were taken at suitable magnification.
2.4.2 Particle size and distribution
Size and size distribution (PDI) of optimized formulation was
determined by laser diffractometry using Beckman Coulter
DelsaTM Nano C Particle Analyzer. For the measurement of
size and PDI, 2 ml of nanolipid carrier was placed into cuvettes
of Beckman coulter, and measurements were recorded. Size
and PDI of NLC containing docetaxel were determined.
2.4.3 Charge on the particle
Particle charge determines physical stability of nanolipid
carrier. Particle charge is quantified as zeta potential, which
is measured via electrophoretic mobility of particles in an
electrical field. The colloids with high zeta potential (nega-
tive or positive) are electrically stabilized and with low zeta
potential tends to coagulate. Zeta potential was measured
using Beckman Coulter DelsaTM Nano C Zeta Sizer.
2.4.4 Differential scanning calorimetry
Differential scanning calorimetry (DSC) is a thermo-
analytical technique which is used to study degree of crys-
tallinity and polymorphic transitions or thermal transitions
involving energy changes during the process of formulation.
The phase transition of docetaxel nanolipid carrier was
analyzed by differential scanning calorimetry (DSC model,
TA instruments, Q-20, USA) in a perforated aluminum
sealed 50-μl pan at a heating rate of 10 °C/min from 30 to
300 °C using nitrogen as blanket gas (20 ml/min).
2.4.5 Entrapment efficiency
Percent drug entrapment was determined and expressed as
the ratio of experimentally measured amount of drug in
dispersion and initial amount used for entrapment. Two
milliliters of suspension (undiluted) was dropwise applied
on the top of the gel bed of the Sephadex minicolumn.
Columns were centrifuged in centrifuge (R-24C, Remi
Instruments, India) at 3,000 rpm for 3 min to remove unen-
trapped drug. Elute was removed and 2 ml saline was applied
to each column and centrifuged as previously mentioned.
Amount of drug entrapped in the nanolipid carriers was then
determined by disrupting the vesicles by adding SLS (0.3%,
w/v) in phosphate-buffered saline (PBS) pH 7.4 and heating
for 20 min and bringing it to room temperature which was
centrifuged at 10,000 rpm for 10 min and assayed for drug
content by UV spectrophotometer at 231 nm.
The percentage drug entrapment was measured as:
% DEE ¼ Amount of drug entrapped
Amount of drug added
 100
The individual values for triplicate determinations and their
mean values were reported.
2.5 In vitro characterization of gel
Optimized formulation was characterized for various param-
eters like rheological studies, mucoadhesive strength, and in
vitro drug release.
2.5.1 Rheological studies
Rheological behaviors of the gel were investigated by study-
ing their viscosity as functions of temperature in Brookfield
R/S plus Rheometer CPS were employed to determine the
rheological properties of NLC in gel systems using CPS 25
spindle equipped with a cone and plate test geometry. The
viscosity of each sample was determined before and after
gel formation by adjusting the temperature of the sample
holder. Since the pluronic F127 gel (20 % solution) in the
range of 32 to 34 °C, estimation was conducted at 30 and
35 °C. Each point is the mean of three readings.
2.5.2 Mucoadhesive strength
Mucoadhesive forces of all the prepared formulations were
determined using a mucoadhesive force measuring device,
which is a modified balance. This balance was developed in
our laboratory with slight modifications, according to the
previously reported methods. The mucoadhesive force of
the formulations under examination was determined by
measuring the force required to detach the formulation from
breast tissue detached from Wistar rats attached to one side
using the measuring device. At the right arm of the balance,
breast tissue was horizontally glued to the lower surface of
the right pan of the modified balance. The tissue was at-
tached to one side and was hydrated with distilled water
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prior to the mucoadhesion test. One milliliter of formulation
was placed on the upper surface of slide.
The upper stage of the modified balance containing the
hydrated breast tissue of Wistar rats was adjusted to be in
contact with the preparation. The water was allowed to drip
from the infusion set into a preweighed plastic jar placed
on the left pan of the balance at a constant rate. The
dripping of water was stopped when the tissue was
detached from the tested sample, the filled plastic jar was
reweighed, and the mass of water required to detach the
tested sample from the tissue was calculated from the
difference. Measurements were repeated three times for
each of the gel preparations, but a fresh tissue and smooth
gel surface was created before each measurement. The
weight required for the detachment was calculated, and
mucoadhesive strength was determined according to the
formula given below.
Mucoadhesive Strength ¼ Force of Adhesion Area=
wherein Force of Adhesion ¼ ðm gð Þ g accdueto gravityð Þ=
1;000.
2.6 In vitro drug release
2.6.1 In vitro drug release from nanolipid carrier
In vitro drug release studies were performed by dialysis bag
method using shaking incubator (LSB-1005 RE Daihan
Labtech Co. Ltd., Korea) at rotation speed of 100 rpm. SLS
(0.3%,w/v) phosphate buffer (pH 7.4) was used as dissolution
medium. Each dialysis bag (pore size 12 kDa, Sigma Chem-
ical Co., USA) was loaded with nanolipid carrier equivalent to
800 μg of drug. Volume and temperature of dissolution
medium were 100 ml and 37.0±0.2 °C, respectively. At
predetermined time interval, samples (3 ml) were withdrawn,
replaced with same volume of fresh media, filtered, and
assayed for drug content at 231 nm against blank using UV–
visible spectrophotometer. Mean results of triplicate measure-
ments and standard deviation were reported.
2.6.2 In vitro drug release from nanolipid carrier in gel
Membrane-less diffusion system was used for studying the
release of docetaxel from pluronic F127 gel as reported
previously. A volume of 2-ml pluronic 127 gel was put in
a flat-bottomed vial (internal diameter about 18 mm)
followed by adding 8 ml physiological saline (0.9 % NaCl,
w/w) gently on the surface of gels, and then the vial was
shaken in a thermostatic shaker (LSB-1005 RE Daihan
Labtech Co. Ltd., Korea) under 37 °C at 40±10 rpm.
Aliquot of 2 ml sample of the supernatant solution was
withdrawn at predetermined.
2.7 Stability studies
Selected and optimized formulations of NLC-DTX were
subjected to stability testing for 30 days in a desiccator at
room temperature. The samples were observed at the pre-
determined time intervals of 1, 10, and 30 days and evalu-
ated for appearance, particle size, and PDI.
2.8 In vitro anticancer activity studies in cell lines
2.8.1 In vitro cytotoxicity studies (MTT assay)
Cell culture establishment and maintenance HeLa and B-16
cell lines obtained from NCCS Pune were maintained in
desired media supplemented with 10 % inactivated fetal bo-
vine serum, 100 U/ml penicillin, and 100 μl/ml streptomycin
incubated at 37 °C and 5%CO2 in humidifier incubator. After
attaining 80 % confluence cells were subcultured by trypsini-
zation with 0.25 % trypsin solution under sterile conditions.
MTT assay The cytotoxicity of various drug solutions was
determined by tetrazolium-based colorimetric assay (MTT
assay). Cells were plated in 96-well plates at 5×103 per
100 μl per well with density determined on the basis of
growth characteristics of each cell line. After overnight
incubation, triplicate wells were treated with varying con-
centration of compounds ranging from 0.01 to 50 μM/ml
and standard docetaxel incubated for 3 days. After 3 days,
medium was replaced with 2 μl of MTT solution (5 mg/ml),
and cells were incubated for 3 h. Formazan crystals were
dissolved in dimethyl sulfoxide (DMSO). The relative per-
centage of metabolically active cells compared with untreat-
ed controls was then determined on the basis of
mitochondrial conversion of MTT to formazan crystals that
were dissolved in DMSO. Formazan crystals were dissolved
in DMSO. Spectrophotometric absorbance of sample was
determined by microplate reader (Biorad) at 570/630 nm.
Concentrations of samples showing 50 % reduction in cell
viability (i.e., IC50 values) were then calculated.
2.8.2 Mechanism of cell death (apoptosis) study
Acridine orange/ethidium bromide assay Cancer cells
grown in six-well plate (12,000 cells/well) were treated with
and without drug for 24 h. B-16 cells were pelleted by
centrifuged at 5,000 rpm for 5 min using a Beckman Model
TJ-6 centrifuge and washed with 1 ml of cold PBS once.
Cell pellets were then re-suspended in 25-ml cold PBS, and
2 ml EB/AO (1:1, 4 mg/ml) dye mix was added. Stained cell
suspensions (10 ml) were placed on a clean microscope
slide and covered with a cover slip. Cells were viewed and
counted using inverted microscope (Olympus CKX 41) at
×400 magnification. Pictures were taken with a Sony color
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video camera. Tests were done in triplicate, counting a
minimum of 100 total cells each. The differential uptake of
these two dyes allows the identification of apoptotic and
non-apoptotic cells (Babykutty et al. 2009).
2.9 In vivo breast tissue homogenate studies
For tissue distribution studies, group of rats (n=4) were
administered with prepared nanolipid carriers at a dose of
200μg/kg. After administration of docetaxel nanolipid carrier,
tissue was collected at various sampling points to determine
the percent drug recovery at different time interval.
Percentage drug recovery from tissue was obtained by
administration of pure drug followed by administration of
prepared nanolipid carrier and nanolipid carrier in gel
through intralesional route. Three groups of rats were taken
for tissue distribution studies. Each group had four rats at
each sampling point. The formulation was administered
intralesionally with a syringe.
2.10 Statistical analysis
All the experiments were carried out three times indepen-
dently. The data obtained were expressed in terms of “mean
±standard deviation” values. These values were analyzed
using two-way ANOVA.
3 Results
3.1 Optimization
3.1.1 Nanolipid carrier
The parameters such as homogenization time, sonication
time, weight ratio of drug to lipids (glyceryl monostearate
and oleic acid), weight ratio of solid lipids to liquid lipids,
and the concentration of pluronic F127 were optimized each
at various levels taking the particle size, PDI, zeta potential,
and entrapment efficiency as response parameter. When one
factor was under investigated, the other three were fixed
(Tables 1 and 2).
Optimized formulation (F14) with 3 min homogenization
time, 4 min sonication time, 200 mg pluronic F68 as sur-
factant, and 10 mg as drug amount was further optimized for
solid-to-lipid ratio keeping all the above-optimized parame-
ters constant at various levels. Particle size and drug entrap-
ment efficiency of NLCs prepared with various amounts of
liquid lipid are given in Fig. 1.
3.1.2 Nanolipid carrier in gel
Various parameters were optimized like polymer concentra-
tion which affects the diffusivity of drug in higher polymer
concentration (like 20 %, 22 % (w/w)) in formulation of
pluronic F127 gel. It was observed that the diffusion coef-
ficients tend to decrease as the polymer content increases
which were also reported for pluronic F127. Polymer con-
centration also affected gelation temperature and gelation
time (Table 3).
The performance criteria for gel depend on physiological
temperature of breast tissuewhich was optimized to 30–32 °C.
The optimum time required by the formulation which under-
went sol–gel transition was 45 s, which was optimum for the
gel to easily get attached to tissue. Thermoreversible gel
enhances the bioavailability of drug at breast tissue by
Fig. 1 Optimization of solid
lipid to liquid lipid
Table 3 Optimization parameters of gel
S.No. Polymer concentration
(%)
Gelation
temperature
Gelation time
1 16 36–38 60
2 18 34–36 45
3 20 30–32 45
4 22 27–29 30
5 24 24–26 30
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immobilizing the formulation at the site so that drug is re-
leased and absorbed for a longer duration of time
3.2 Characterization of nanolipid carrier
In vitro characterization included parameters like morphol-
ogy, size and size distribution, particle charge, DSC, entrap-
ment efficiency, and in vitro drug release.
3.2.1 Morphology
Optimized formulation was visualized under TEM for surface
morphology (Liu et al. 2011. TEM photographs revealed that
nanolipid carriers are spherical in shape. TEM images of
nanolipid carrier of docetaxel are shown in Fig. 2.
3.2.2 Particle size and distribution
Size and size distribution of optimized nanolipid carrier of
docetaxel was determined by photon correlation spectroscopy
method using zetasizer (Bechman Coulter), and the results are
tabulated in Tables 1 and 2. Size and size distribution of
optimized formulation was found to be 123.5 nm with PDI
of 0.218.
3.2.3 Particle charge
Charge on the particles is expressed in terms of zeta poten-
tial, and its determination is useful to evaluate physical
stability of a nanolipid carrier. Zeta potential values deter-
mined for various batches of nanolipid carrier are tabulated
in Table 2. Zeta potential of the optimized batch (F21) of the
nanolipid carrier was −33.44±2.54 mV.
3.2.4 Differential scanning calorimetry
The mixing behavior of solid lipid and lipophilic solubilizer in
the NLC was investigated by DSC (Bunjes et al. 1996; Hou et
al. 2003). It gave information about the melting, crystalliza-
tion behavior, polymorphism, and crystal ordering of the solid
and liquid constituents of the nanolipid carriers. The melting
endotherm of NLC (Fig. 3) showed complete absence of
docetaxel peak, indicating that docetaxel was completely sol-
ubilized inside the lipid matrix of NLC. DSC thermogram of
Fig. 2 TEM photograph of
nanolipid carrier of docetaxel
Fig. 3 DSC of nanolipid carrier Fig. 4 Graph explaining the rheological behavior of gel
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NLC showed endothermic with lower onset temperature
(49.92 °C) and peak temperature (53.37 °C) values from those
of the bulk lipid material (Pople and Singh 2011).
3.2.5 Entrapment efficiency
Entrapment efficiency of docetaxel nanolipid carrier was esti-
mated and repeated three times. All the formulations showed
good reproducible results (Table 2). Entrapment efficiency of
docetaxel was found to be 85 %±3 confirming good entrap-
ment efficiency of nanolipid carrier. Most solid lipids form
highly crystalline particles, with a perfect lattice leading to
drug expulsion. On the other hand, the imperfection (lattice
defects) of the lipid structure could offer space to accommo-
date the drug. Modification of lipid by incorporation of lipo-
philic solubilizer molecules might have resulted in the
formation of less perfect crystals with many imperfections
offering space to accommodate the dissolved drug. The mini-
mum amount of solubilizer used (just required to dissolve the
drug) might be responsible for complete immobilization of
liquid nanodroplets of drug in the crystal imperfections of solid
lipid avoiding ejection of the liquid lipid during the crystalli-
zation process at the cooling step (Westesen et al. 1997).
3.3 Characterization of gel
3.3.1 Rheological studies
Rheological studies revealed that the viscosity of the NLCs
remained almost constant up to 30 °C followed by sudden rise
in viscosity up to 37 °C. Beyond this temperature, no rise in
viscosity is observed (Fig. 4). This indicates that the phase
transition from sol to gel starts at 30 °C and complete conver-
sion to viscous gel would take place at 37 °C. This is indicated
by no rise in viscosity once the gel is completely formed.
3.3.2 Mucoadhesive strength
Good mucoadhesive behavior is a prerequisite for a gel to
exhibit long residence time for effective and complete ab-
sorption and sustained action. This property is determined in
terms of force of adhesion in dynes or mucoadhesive force
in dynes per square centimeter. The 20 % pluronic gel
showed force of adhesion of 36.09±0.73 dyne and mucoad-
hesive force 3.07±0.175 dyne/cm2 (Table 4).
4 In vitro drug release
Cumulative release of docetaxel from PF127 gel at 37 °C
was displayed in Fig. 5. It was obvious that docetaxel
released much slower from docetaxel-NLC in Gel than
from plain drug suspension of docetaxel and NLC of
docetaxel. In the first 16 h, about 28 % of DTX was
released from DTX-NLC and DTX-NLC in gel formulation
against 96.14 % of DTX form plain drug suspension.
Thereafter, release rate of DTX from DTX-NLC formula-
tion was faster up to 35 h when the maximum drug release
(96 %) was reached while in case of DTX-NLC in gel, the
same rate of drug release was continued up to the
Table 4 Optimization of force
of adhesion and mucoadhesive
force
S.No. Polymer concentration (%) Force of adhesion (dyne) Mucoadhesive force (dyne/cm2)
1 16 28.23±0.65 2.51±0.08
2 18 32.39±0.95 2.9±0.215
3 20 36.09±0.73 3.07±0.175
4 22 39.33±0.27 3.4±0.270
Fig. 5 Comparison of
cumulative drug release of DTX
from NLC in gel, NLC, and
plain drug suspension
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maximum of 96 % in about 53 h. These results clearly
show that the maximum drug release in all three formula-
tions was 96 % of the total drug but rate and style of
release was different. Plain drug suspension showed initial
burst release of 45 to 50 % drug in about 1.5 h followed by
slower release up to the maximum of 96 % in 16 h. Both
DTX-NLC and DTX-NLC in gel formulations showed
continuous release up to 96 % in 35 and 53 h, respectively.
However, the release was quite faster in case of DTX-NLC
than from DTX-NLC in gel formulation. The difference
between the release properties of DTX from plain drug
suspension and DTX-NLC and DTX-NLC in gel is evi-
dently attributed to the prolonged release function of NLC
in gel. Docetaxel is present in dissolved state in NLC, and
the release is possible into aqueous media by partitioning
which would be obviously very slow. In addition, release
of docetaxel from the drug-loaded NLC in gel has to
partition from NLC into the gel media in the first phase
and then transfer to the aqueous dissolution media by
partitioning and diffusion across the viscous gel. The re-
lease kinetic of docetaxel from DTX-NLC in gel showed
linear curve (r2=0.997) when root of time was plotted
against cumulative drug release (Higuchi model) indicating
which indicated that the drug released by dissolution and
diffusion.
5 Stability studies (Souza et al. 2011)
The results of stability studies indicated no change in particle
size and PDI of formulation till 10 days, but there was slight
increase in particle size from 123.5 to 153.2 nm in 30th day
sample. However, the formulation was clear up to 30 days
(Fig. 6).
6 In vitro anti cancer activity in cell line
6.1 Cytotoxicity studies (MTT assay)
6.1.1 Dose-dependent studies
The comparative cytotoxicity studies of different formula-
tions like plain drug suspension, docetaxel nanolipid carrier,
and nanolipid carrier in GEL were done using MTT assay.
Percentage cell viability of all formulations at different
concentrations in HeLa cell lines and B-16 cell line was
evaluated and presented in Fig. 7. NLC of docetaxel showed
a clear dose-dependent cytotoxicity against these cells with
DTX at an equivalent dose from 0.01 to 50 μM/ml. The IC50
values calculated for docetaxel plain drug suspension, NLC-
DTX, and NLC-DTX in gel was shown in Table 5.
Fig. 6 Average particle size
and PDI of nanolipid carrier
during stability study
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AFig. 7 Comparison of MTT
assay of formulations on HeLa
cell lines (a) and B-16 cell line
(b)
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6.1.2 Time-dependent cell viability studies
The comparative cytotoxicity studies of different formula-
tions like plain dug suspension, docetaxel nanolipid carrier,
and nanolipid carrier in GEL were done using MTT assay.
Percentage cell viability of all formulations at different
concentrations in HeLa cell lines was evaluated after expo-
sure for varied time duration (24, 48, 72, and 96 h) and is
presented in Fig. 8.
6.2 Cell death [apoptosis] studies
The induction of nanolipid carriers mediated cell apoptosis
was observed by acridine orange/ethidium bromide double
staining of treated cell nuclei with optimized dose of nano-
carrier lipid. Microscopic images of the dual stained cells,
presented in Fig. 9, show that the live cell nuclei stained
green due to acridine orange uptake and their numbers
gradually decreased with time owing to more cell death
figure, which correlates with the TEM images. One can
observe progressive nuclear uptake of ethidium bromide
due to cell membrane perforation during apoptosis, which
stained nuclei red, and such an effect was prominent in 24 h.
Microscopic images of treated as well as untreated cells at
24 h indicate that live untreated cells had well-organized
chromatin structures, whereas the treated cells had frag-
mented or condensed chromatin consisting of apoptotic
nuclei. Therefore, the nuclear staining experiment shows
that apoptosis was seen in 24 h after addition of nanolipid
carrier to the culture medium.
7 In vivo breast homogenate studies
Tissue homogenate studies were performed to determine the
residence time of docetaxel after local intralesional admin-
istration of the drug into breast tissue as plain drug suspen-
sion in water, DTX-NLC, and DTX-NLC in gel. Drug
concentration estimated in breast homogenate samples at
definite time intervals is shown in Fig. 10. The results
indicated maximum residence time of the formulation and
drug concentration in case of DTX-NLC in gel followed by
DTX-NLC and then plain drug suspension. The drug
released from DTX-NLC in gel took prolonged time (60 h)
to get almost cleared from the breast tissue while it was 36 and
24 h in case of DTX-NLC and plain drug suspension, respec-
tively. Thus, the study revealed that enough amount of drug
was reaching into retained in the effector organ for long time
in a controlled manner (Fig. 10).
8 Statistical analysis
All the experiments were carried out three times independent-
ly. The data obtained were expressed in terms of “mean±
standard deviation” values. These values were analyzed using
two-way ANOVA, and results were found to be significant
with p<0.001.
9 Discussions
Investigations have been made on other delivery approaches
for various gynecological cancers like breast cancer which
have widely spread in world among females. Docetaxel is a
potent anti-cancer drug used in treatment of breast cancer
which possesses many unavoidable side effects, and various
approaches have been developed with intravenous infusion
or I.V. bolus to produce sustain effect with limited success.
The present investigation is focused on the local delivery of
drug into the tumor as a better method in administrating the
drug. The work performed in this present study has also
used novel approaches of using docetaxel-loaded NLC and
DTX-NLC in pluronic gel to improve the residence time of
the formulation in the effector organ after intralesional in-
jection into breast tissues. The structural integrity of NLC
containing liquid and solid lipid core could increase the
solubility of docetaxel; the optimal zeta potential and parti-
cle size of NLC could keep docetaxel stably entrapped in
inner core of NLC (Hu et al. 2006). This system was
incorporated into pluronics 127 which is composed of an
outer shell of hydrophilic PEO and a hydrophobic PPO core,
which possess thermoreversible property which is in sol
form at low temperature and gets converted into gel at
physiological temperature.
Table 5 IC50 value of formulation
Formulation IC50 value B16 (μM) IC50 value HeLa (μM)
Plain drug suspension 0.88±1.03 0.92±1.21
NLC 8.97±2.09 9.2±1.99
NLC in gel 11.96±1.51 11.68±2.21
Fig. 8 Percentage cell viability after exposure with different formula-
tions for varied time duration on HeLa cell line
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The difference between the release properties of doce-
taxel from plain drug suspension, NLC of docetaxel, and
NLC in gel is evidently attributed to the prolonged release
function of NLC in gel. Docetaxel being lipophilic in nature
was held by the lipid core of the NLC and the drug released
mainly through dissolution and diffusion. This result im-
plied that docetaxel could be released slowly from NLC of
docetaxel and could keep constant concentration for rela-
tively long period. Therefore, NLC of docetaxel in gel might
reduce frequent administration of drug which was desired
clinical application of this project.
NLC of docetaxel and the NLC in gel showed decreased
cytotoxicity than free docetaxel against both B-16 and HeLa
cell lines. However, Paola et al. (2012) reported that the anti-
proliferative effect of docetaxel appeared much earlier when
the drug was encapsulated in lipid nanoparticles than when it
was free when subjected to flow cytometric studies with breast
carcinoma (MCF-7) cells. In addition, Xu et al. (2009) reported
increased anti-tumor activity of docetaxel-loaded hepatoma-
targeted solid lipid nanoparticle (SLN) prepared with galacto-
sylated dioleoylphosphatidyl ethanolamine in comparison to
taxotere or docetaxel-loaded nontargeted SLN following IV
injection. In most of these experiments, it is clear that the
increased activity of docetaxel-loaded lipid nanoparticles is
by increased uptake of these particulates by enhanced perme-
ation and retention mechanism and may also due to avoidance
of efflux process. Till today, no reports are available to authen-
ticate the uptake of intralesionally injected lipid nanoparticles
by tumor tissue intact. Hence, the advantage of intralesional
injection is due to avoidance of systemic side effect and
improved therapeutic efficacy as a result of sustained release
of the anticancer agent loaded in lipid particles or in gel system.
Decreased anticancer activity of docetaxel-loaded NLC and
the NLC-loaded gel in comparison to docetaxel as observed in
our experiments is also due to slow rate of uptake of nanolipid
carriers, and the docetaxel release from these NLCs is the
critical factor for the drug uptake by cells. Colloidal delivery
systems like NLCs administered by intramammary injection
Fig. 9 Fluorescence micrographs (magnification ×400) of acridine/
ethidium bromide stained B-16 mouse melanoma cell line. a, d Unex-
posed (control cells have normal green nucleus indicating live cells). b,
e Cells exposed to IC50 (0.88 and 11.96 μg/ml) of plain drug and NLC
in gel, respectively, for 24 h bright green nucleus with condensed or
fragmented chromatin suggesting apoptosis. c, f Cells exposed to IC50
(0.88 and 11.96 μg/ml) of plain drug and NLC in gel, respectively, for
24 h have a structurally normally orange nucleus indicate necrosis
Fig. 10 Percent drug recovered
in breast tissue
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could yield high local concentration in the breast tissue and its
associated lymph drainage area (Berg and Christophersen
1956). Similar conclusions were also drawn by Mendes et al.
(2009) based on their work on the uptake by breast carcinoma
and lymph nodes of a lipidic nanoemulsion after intralesional
injection into the patients. Luciano et al. (1995) also reported
that the potentiation of the antitumor actions of IFNs adminis-
tered by intramammary injection to human breast cancer xen-
ografts growing bilaterally in nude mice was effective at the
local but not at the systemic level indicating that the drug
accumulation in the local area of breast tissue is a critical factor
in breast tumor regression.
In vivo breast tissue homogenate studies were performed
to determine the local drug concentration reaching into
targeted organ through increased residence time due to slow
release of the drug from the DTX-NLC and DTX-NLC in
gel formulations. In vivo results matched with the release
pattern of in vitro release profile of the drug. The results
revealed that enough amount of drug released was retained
in the organ in a controlled manner with slow elimination
from the body. The organ distribution study confirmed that
drug released from the gel was in a controlled manner which
meets the desired application of nanolipid carrier in gel.
10 Conclusions
In the present study, we first developed a NLC system which
was incorporated into pluronic 127 gel which possesses
thermosensitive property. In addition, its capacity to trap
poorly soluble drug in NLC was insensitive to temperature.
According to our study data, the release of docetaxel from
NLC in gel in vitro and in vivo was sustained for more than
60 h. The NLC in gels can solubilize and stabilize DTX.
However, anti-tumor activities of docetaxel-loaded NLC
and the NLC in gel were lower than plain docetaxel when
tested on B-16 and HeLa cell lines in vitro. Specific admin-
istration, such as intralesional delivery, likewise improved
the local drug concentration around tumors and could en-
hance the therapeutic effects of NLC in gel against breast
tumor. As a consequence, local administrations of docetaxel
in NLC system appeared to be good physical targeting
approaches for solid tumor treatment. At the same time,
they provide scientific basis for further studies regarding
the application of thermosensitive gel loaded with water-
insoluble drugs in other clinical cancer therapy studies.
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